论文部分内容阅读
目的比较培美曲塞与吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取2012年6月—2013年2月徐州市中心医院收治的NSCLC患者60例,采用随机数字表法分为对照组和观察组,每组30例。观察组患者给予培美曲塞联合顺铂治疗,对照组患者给予吉西他滨联合顺铂治疗。比较两组患者临床疗效、生存情况及毒副作用发生情况。结果两组患者临床疗效、中位生存期、12个月生存率、18个月生存率比较,差异无统计学意义(P>0.05)。两组患者恶心、呕吐、便秘、食欲不振、丙氨酸氨基转移酶增高、乏力、低钙血症、腹泻、肾功能异常、低清蛋白血症、口腔炎发生率比较,差异无统计学意义(P>0.05);观察组患者白细胞减少症、血红蛋白降低、血小板计数降低、脱发发生率均低于对照组(P<0.05)。结论培美曲塞与吉西他滨分别联合顺铂治疗初治晚期NSCLC的临床疗效相当,但前者用药安全性较高。
Objective To compare the clinical efficacy of pemetrexed and gemcitabine in combination with cisplatin in the treatment of newly diagnosed advanced non-small cell lung cancer (NSCLC). Methods Sixty NSCLC patients who were admitted to Xuzhou Central Hospital from June 2012 to February 2013 were randomly divided into control group and observation group with 30 cases in each group. Patients in the observation group were treated with pemetrexed combined with cisplatin, and patients in the control group were treated with gemcitabine plus cisplatin. The clinical efficacy, survival and side effects of the two groups were compared. Results There was no significant difference in clinical efficacy, median survival, 12-month survival and 18-month survival between the two groups (P> 0.05). There was no significant difference in the incidence of nausea, vomiting, constipation, loss of appetite, increased alanine aminotransferase, fatigue, hypocalcemia, diarrhea, renal dysfunction, hypoalbuminemia and stomatitis in both groups (P> 0.05). The leukopenia, hemoglobin, platelet count and hair loss in the observation group were lower than those in the control group (P <0.05). Conclusion Pemetrexed and gemcitabine combined with cisplatin in the treatment of newly diagnosed advanced non-small cell lung cancer (NSCLC) have similar clinical efficacy, but the former is more safe to use.